The pharmaceutical company Moderna claims that a crucial stage of the last round of scientific testing has been completed for its concomitant flu and COVID vaccine, which tackles both illnesses in one dose.
The vaccination provides the body with defensive antibodies, according to the phase-three experiment.
According to the results, it works just as well as separate flu and COVID doses.
According to Moderna, fewer injections would be more practical and easy.
CEO Stephane Bancel expressed his optimism to News that the messenger ribonucleic acid (mRNA) vaccination might become widely accessible by 2026, or possibly even before.
“We are very delighted about the results, because it’s the first time in the world that a company is able to show positive phase-three results combining in a single dose flu and COVID vaccine,” he stated.
“You get one dose, one needle,” which translates to “consumer ease and peace of mind.”
A comparable two-in-one mRNA vaccine against the flu and Covid is being tested by rival companies Pfizer and BioNTech.
Scientists anticipate that mRNA vaccines will be more quickly developed and updated than the flu shots currently in use, and that they will better fit evolving strains of the virus.
The mRNA-1083 vaccination elicited a greater immunological response in the ongoing Moderna study compared to the approved comparator vaccinations.
